Information Journal Paper
APA:
Copy. (2018). Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 54(-), 112-117. SID. https://sid.ir/paper/758383/en
Vancouver:
Copy. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY[Internet]. 2018;54(-):112-117. Available from: https://sid.ir/paper/758383/en
IEEE:
Copy, “Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial,” INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. 54, no. -, pp. 112–117, 2018, [Online]. Available: https://sid.ir/paper/758383/en